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linked immunosorbent assay kit.
Results:MeanserumKL-6 levels+/2 standarddeviation forBMTsub-
jects with BOS, BMT subjects without BOS and healthy controls were
571.6 +/2350.5, 302.3 +/287.3 and 209.1 +/277.6 U/ml, respectively.
The difference between BMT subjects with BOS and those without
BOS was statistically significant (p 5 0.003) as well as those with BOS
and healthy controls (p 5 0.001). There was no statistical difference
between BMT subjects without BOS and healthy controls (p5 .956).
Conclusions: KL-6 levels were significantly elevated in BMT sub-
jects with BOS as compared those without BOS and healthy controls.
KL-6 could serve as a diagnostic tool in detecting BOS in BMT
recipients.Table 1. Phase II Trial Clinical Outcomes
Clinical Outcome Incidence
Confidence
Interval
Cumulative Incidence of Grade II-IV aGVHD 13% (0.05-0.25)
Cumulative incidence of death without grade
II-IV aGVHD before day 100
13% (0.05-0.250)
Overall non relapse mortality 26% (0.16-0.41)
cGVHD 28% (0.17-0.43)
Relapse 17% (0.09-0.31)
TTP 4.4% (0.03-0.2)
CMV PCR 31% (0.19-0.45)
EBV PCR 20% (0.1-0.33)
HSV stomatitis & BK cystitis* 13% (0.06-0.26)
Bacterial infections 60% (0.45-0.73)
Oral candidiasis 6.7% (0.02-0.17)
SOS 6.7% (0.02-0.17)
*This incidence is for each of the the two viral infections.380
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION VERSUS BONE
MARROW TRANSPLANTATION IN SEVERE APLASTIC ANEMIA
Ghavamzadeh, A., Alimoghaddam, K., Hamidieh, A.A., Jalili, M.,
Bahar, B., Iravani, M., Mousavi, S.A., Jahani, M. Tehran University
of Medical Sciences, Tehran, Islamic Republic of Iran
Introduction: Severe Aplastic Anemia (SAA) is a rare disease and the
outcome of these patients has improved with hematopoietic stem cell
transplantation (HSCT). In patients who have anHLA-identical sib-
ling donor, HSCT is the preferred treatment. This is a retrospec-
tively study in patients who received bone marrow (BMT) or
peripheral blood stem cell transplantation (PBSCT) and compared
the differences in hematologic recovery, acute and chronic
GVHD, relapse and disease free survival and overall survival in
two groups.
Methods: Totally 173 patients with diagnosis of SAA between
March 1991 and October 2010, received allogeneic hematopoietic
stem cell transplantation from an HLA-identical sibling donor (167
patients) orHLA fullmatched other related donor (6 patients).Three
patients exclude from study because received both bone marrow and
peripheral blood.Median age in BMTgroup was 17 years (range 1 to
32 year) and in PBSCTwas 23 years (range 2 to 50 year). All patients
received the conditioning regimencontaining cyclophosphamide and
ATG as our center protocol and cyclosporine and methotrexate for
graft-versus-host disease (GVHD) prophylaxis.
Result: The median of follow-up was 40 and 20.5 month in BMT
and PBSCT group respectively. The median time to reach ANC $
500/mm3 and platelet $ 20000/ml in PBSCT group (11 and 17
days, respectively) was significantly lower than BMT group (16
and 19 days, respectively) (P\ 0.001). In two groups there was no
difference in the incidence of acute GVHD (p 5 1.0). The cumula-
tive incidence of chronic GVHD for those who survived more than
90 days was 10.2% in the BMT group, compared to 27% in the
PBSCT group (p 5 0.022). Relapse of disease occur in twelve
(24%) patients among BMT recipients and in 8 (6.5%) patients of
PBSCT recipients (p 5 0.005). Disease-free survival at 1 year was
74% in the BMT group and 86% in the PBSCT group (p 5 0.24)
and Overall survival at 1 year was 82% in the BMT group and
89% in the PBSCT group (p 5 0.8). Nine patients in BMT group
and 19 patients in PBSCT group were dead.
Discussion:However it seems that bone marrow is preferred source
for progenitor cell for SAA transplantation but this study results
showed that there was no difference in overall survival and disease
free survival in two groups. But engraftment was rapid in multi-
transfused patients who undergoing PBSCT than BMT with
significant differences.381
PHASE II TRIAL: THE COMBINATION OF TACROLIMUS, SIROLIMUS, AND
RABBIT ANTI-THYMOCYTE GLOBULIN (THYMOGLOBULIN THYMO) TO
PREVENT ACUTE GRAFT-VS.-HOST DISEASE (AGVHD) IN PATIENTS RE-
CEIVING UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION
(UHSCT)
Al-Kadhimi, Z.1, Gul, Z.1, Rodriguez, R.2, Chen, W.3, Mitchell, A.1,
Abidi, M.1, Ayash, L.1, Deol, A.1, Lum, L.1, Ratanatharathorn, V.1,Uberti, J.1 1Wayne State University/Karmanos Cancer Center, Detroit,
MI; 2Southern California Kaise Permenante/City of Hope Medical Cen-
ter, Los Angeles, CA; 3Wayne State University/Karmanos Cancer Center,
Detroit, MI
Background: Acute graft versus host disease continues to affect ap-
proximately 60% of patients undergoing UHSCT, with significant
mortality and morbidity.
Methods: We prospectively evaluated the efficacy of combining
Thymo (4.5 mg/kg divided doses on days -1,-2, and -3), Tacrolimus
and Sirolimus in preventing aGVHD. The cumulative incidence rate
at 100 days of grade II-IV aGVHDwas calculated using death without
grade II-IV aGVHD as competing risk. The median time to relapse,
defined as time from BMT to the event of relapse or death due to re-
lapse, was reported using KM method. The proportions of relapse,
non-relapse mortality, cGVHD, and incidence of infections were re-
ported with the Wilson’s 95% Confidence Interval (in table below).
Results: Between August 2008 and August of 2010, 45 patients (pts)
were enrolled, with median age of 53(20-70) years. The Median fol-
low-up time is 10.5 months (1.3-26.5). There were 20 AML, 11
MDS, 4 ALL, 2 CML, 1 CLL, 3 Myelofibrosis, 2 multiple myeloma,
2 NHL pts. Preparative regimens included Bu/Flu (29), Bu/Flu-TBI
(9), VP16/TBI (3), R-BEAM (1), and Flu/MEL-TBI (3). All pts re-
ceived peripheral blood stem cells mobilized with G-CSF. Median
CD34+ dose was 7.31x106 /kg (1.9-18.6). Twenty pts received 8/8
and 25 received 7/8HLAmatched grafts respectively. All patients’ en-
grafted,withmediandayof 12 (9-18).Sixteendeaths occurred through-
out the entire follow up period, due to: relapse (4), aGVHD (2),
cGVHD (3), sinusoidal obstruction syndrome (SOS) (1), bleeding
(1), multi organ failure (2), sepsis (2) and pneumonia (1). Eight patients
experienceddisease relapse.Twelvepatientshadnon-relapsemortality.
Thirteen pts developed aGVHD, 7 grade I, 3 grade II, 2 grade III,
and 1 grade IV. The cumulative incidence rate for grade II-IV
aGVHD at 100 days is 0.13 (0.053, 0.250); the cumulative incidence
rate of the competing event death without grade II-IV aGVHD at
day 100 is 0.13 (0.053, 0.250). Thirteen pts developed cGVHD.
There were 2 cases of thrombotic thrombocytopenic purpura
(TTP) before day 100. 14CMVby PCR, 9 EBV by PCR, 6HSV sto-
matitis, 6 BK cystitis, 27 bacterial infection, 3 oral candidiasis, and 3
SOS. The median time to relapse was 18.38 months.Conclusion: These early results suggest that the combination of
Thymo, Tacrolimus and Sirolimus in pts undergoing UHSCT is
well tolerated and is associated with a low rate and severity of acute
GVHD. Six months follow up data will be presented at the meeting.
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EFFECT OF RELATED AND UNRELATED DONOR HAEMATOPOIETIC STEM-
CELL TRANSPLANTATION ON OUTCOME IN ADULTS WITH HIGH RISK
HEMATOLOGICAL DISEASE: AN INTENTION-TO-TREAT ANALYSIS OF
410 PATIENTS AT A SINGLE CENTER INSTITUTION
Lupo-Stanghellini, M.T.1, Forno, B.1, Marcatti, M.1, Bitetti, C.1,
Coppola, M.1, Assanelli, A.1, Greco, R.1, Lunghi, F.1, Tassara, M.1,
S292 Poster Session IIGuggiari, E.1, Carrabba, M.1, Matteazzi, F.1, Camba, L.1, Clerici, D.1,
Malato, S.1, Marktel, S.2, Bonini, C.3, Bordignon, C.4, Corti, C.1,
Bernardi, M.1, Peccatori, J.1, Ciceri, F.1 1San Raffaele Scientific Institute,
Milan, Italy; 2San Raffaele Scientific Institute, Milan, Italy; 3San
Raffaele Scientific Institute, Milan, Italy; 4Universita Vita Salute San
Raffaele, Milan, Italy
Allogeneic stem cell transplantation (SCT) from an HLA-
matched related (MRD) or unrelated donor (MUD) is a curative op-
tion for patients (pts) with high-risk hematological disease (HRHD).
In the absence of a MRD/MUD, pts have been offered investiga-
tional SCT strategies such as umbilical cord blood (UCB) or family
haploidentical SCT (HAPLO). In our Institution, all patients with
HRHD are typed at entry; if aMRD donor is missing aMUD search
is promptly activated. AHAPLO is offered to pts lacking anMRDor
MUD in order to adequately treat HRHD in the appropriate time,
according to clinical indications and ongoing protocols. Here we re-
port the intention-to-treat (ITT) analysis of alternative donor trans-
plantation at our Institution. Data were obtained from Institutional
databases.
Between Jan-2004 and July-2010, 410pts (age 48y, range 15-76)
received indication to SCT according to EBMT recommendations.
246pts were diagnosed for acute leukemia (AL, 60%). 155pts (46%)
were transplanted in persistence of disease (PD).
89pts (22%) received a transplant from a MRD; 190pts (46%) ac-
tivated aMUD search; 84pts (20% of total, 44% ofMUD searching)
received a MUD transplant; 42pts (10%-21%) a HAPLO due to
lacking of a suitable MUD; 11pts (3%-6%) a UCB. 149pts received
a HAPLO (36%, 107 up-front). 21pts died before SCT (5%), 37
(9%) are still searching for a suitable donor and a donor is under eval-
uation for 19pts (5%).
The median time from diagnosis to SCT was 165 days, from
MUD search to SCT 103 days.
The overall survival (OS) analysis in ITT is 51% at 1 year, 39% at
3y, for pts transplanted in complete remission (CR) 74% and 57%,
for pts transplanted in PD 29% and 21% (p\ 0.0001). The OS
according to donor source (MRD-MUD-HAPLO) is comparable
(p 5 ns) in pts transplanted in CR.
In the AL setting the 1y OS/transplant related mortality (TRM)/
relapse incidence (RI) is 51%-27%-40% respectively; for pts trans-
planted in CR 77%-20%-25%, for pts transplanted in PD 20%-
41%-67%. The outcome analysis per donor source is comparable
(p 5 ns) within CR setting, while there is a trend of lower RI and
TRM in the HAPLO vs MRD in PD pts.
In ITT 81% of overall pts received a SCT. The outcome achieved
for pts transplanted in CR is comparable within the major donor
sources (MRD-MUD-HAPLO). This result confirm the need to of-
fer to every candidate pts a transplant option in the appropriate time
and support the use of alternative donors, particularly HAPLO, in
absence of an available MRD or MUD.
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MINIMAL RESIDUAL DISEASE STATUS AT DAY +100 POST ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION IS A POWERFUL PRE-
DICTOR FOR POST-TRANSPLANT OUTCOME IN PATIENTS WITH HIGH
RISK ACUTE LEUKEMIA
Tang, X., Sun, X., Shi, X., Xue, S., Zhu, M., Shen,W., Sun, A., Wu, D.
Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow
University, Suzhou, Jiangsu, China
Background and Objectives: Relapse after allogeneic hematopoi-
etic stem cell transplantation (allo-HSCT) is still a major cause for
the failure in treatment. The application of multiparameter flow cy-
tometry (MFC) for minimal residual disease (MRD) assessment in
high risk patients with acute leukemia (AL) who undergoing allo-
HSCT was little concerned. We retrospectively analyzed the serial
results ofMRDof 52 high risk patients with AL to evaluate the prog-
nostic value of MRD pre and post transplantation.
Methods: 52 patients with a median age of 29 (13–55) years have
been enrolled on this study. Diagnoses included AML (n 5 27)
and ALL (n 5 25). The patients had been analyzed retrospectively
the level ofMRDpre-(day-30)and post-HSCT(day+30 and +100)us-
ing three color FCM with CD45/SSC gating and a comprehensive
panel of monoclonal antibodies, at least one leukemia associated ab-
errant immunophenotype (LAIP) at diagnosis. According to the cutoff value 0.1%, two groups were defined based on the level of pa-
tient’s MRD level\ (low level group) or . 5 (high level group)
0.1%.
Results: The median follow up were 23 (range 1-60) months.
1.MRD level declines significantly (P 5 0.03) post transplant. 2.
There were significantly difference between low level and high level
group at day -30 (before transplant) with 3 years event free survival
(EFS) and relapse free survival (RFS) (77.4% vs. 22.3%, p 5 0.007
and 88.4% vs. 25.7%, p 5 0.001 respectively). 3. Concerning about
MRD at day +100 after transplant, the outcomewas significantly bet-
ter among patients with low level MRD group versus high group in-
cluding 3 years EFS and RFS (79.5% vs. 9.5% and 89.5% vs.11.2%,
both p\ 0.001). And the cumulative incidence of relapse for two
groups were 7.4% and 80.9% (P\0.05) respectively. 4. The median
time from first time with high level MRD detected to clinical relapse
was 2.5 (range from 1 to 33) months in relapsed patients. 5. The pa-
tients with cGVHDhad better 3 yearsOS and EFS than that without
cGVHD (86.3% vs 12.1%, p\ 0.001 and 65.3% vs.14.8%, p\
0.001 respectively). 6. Multivariate Cox regression analysis revealed
that MRD on day +100 as well as chronic GVHDwere independent
parameters predictive for OS and EFS.
Conclusions:MRDmonitoring pre- and post-transplant are impor-
tant tools to predict the outcome of transplantation for patients with
high risk AL. The MRD check point at day +100 should be consid-
ered crucial for subsequent therapeutic decisions after allogeneic
transplantation.384
DEVELOPMENT OF ADJUVANT ANTIVIRAL IMMUNOTHERAPY AFTER CBT
USING DENTRITIC CELL VACCINATIONS
Flinsenberg, T.W.H., Compeer, E., Beekman, J.M., Boelens, J.J.,
Boes, M.L. Wilhelmina Childrens Hospital, Utrecht, Netherlands
Purpose: Elicit potent CD8+ T cell responses by dentritic cell (DC)
vaccination to reduce viral reactivations in children and adults after
cord blood transplantation (CBT).
Background: Although CB grafts have multiple advantages over
conventional stem cell grafts, relapses and viral re-activations remain
serious obstacles in children undergoing CBT. New strategies are
needed to increase early specific adaptive immune responses after
CBT in order to establish full clearance of, and long-term immuno-
logical memory against viruses.
Improvement in the presentation of viral-antigens by vaccination
with viral-antigen loaded DCs may induce mass expansion of anti-
gen-specific cytotoxic T lymphocytes (CTLs) in vivo, and subse-
quently reduce the risk of disease caused by viral re-activation after
CBT. In mice, cross-presentation is induces after antigen uptake
by the Fc receptor (FcR). We aim to improve the elicitation of virus
specific CTLs, by targeting FcR mediated antigen uptake by DCs.
Methods: Immature DCs (iDCs) differentiated from the human
CD34 derived DC progenitor cells, and human CB derived
(hDCs) were pulsed with opsonized and non-opsonized EBV secret-
ing B-cell (B-95-8) homogenates, obstained by mechanic cell frag-
mentation. Uptake via FcRs was blocked by using human IgG Fc
fragments or anti-CD16, -CD32 and -CD64 F(ab’)2-fragments.
The amount of cross-presentation was measured through cytokine
production by an EBV specific CD8 T cell clone, both by Elispot
IFN-y measurements and FACS analysis of intracellular cytokine
and proteases production (IFN-y, TNF-a, granzyme B and perforin)
and presence of the late endosomal marker (LAMP-1) on the cell
surface.
Results:We show increased binding and uptake of EBV/B cell frag-
ments when these fragments are targeted to Fc receptors for uptake
by DCs. We have generated multiple CD8 T cell clones that are
TCR specific tot the immunodominant EBV GLCTLVAML pep-
tide (from the EBV lytic protein BMLF1 corresponding to residues
280–288).We are currently testing whether FcR targeting of EBV/B
cell fragments to DCs improves the elicitation of potent CD*+ T cell
responses.
Conclusion:Optimizing cross-presentation inCB derivedDCsmay
be an important and effective tool in the development of adjuvant
anti-viral immunotherapies after CBT to induce early potent anti-vi-
ral responses.
